PPROM Clinical Trial
Official title:
Pro-omega-3, Reduction of Inflammation and Modulation of Prematurity
The aim of the project is to decrease the inflammatory status of pregnant women with preterm premature rupture of membranes to delay the initiation of labour that would inevitably lead to premature delivery. The main objective is to measure the mean duration between the initiation of the treatment and delivery in the two groups treated either with MAG-DHA or with the placebo.
This randomized controlled trial will be conducted in two hospitals in the province of Quebec
(CHUS, CHUQ- Site mère-enfant Soleil).
Patients between 24 and 33 weeks of gestation with a diagnosis of preterm premature rupture
of membranes (PPROM) who meet all inclusion and none of the exclusion criteria will be
approached to participate. Once they have signed the IFC, participants will be randomized and
begin a supplementation with either MAG-DHA or the placebo until delivery or for up to 2
weeks (14 days). A total of 70 patients will be recruited.
Principal outcome: To compare the difference in duration between the start of treatment and
delivery between the group receiving MAG-DHA and the group receiving placebo.
Secondary outcomes: 1) Evaluate the difference in neonatal outcome between children in the
MAG-DHA group and those in the placebo group. 2) Determine the inflammatory status of the
patients associated with the exposure to either MAG-DHA or the placebo.
This regimen could potentially represent an innovative approach in the management of women
with a diagnosis of PPROM.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02939742 -
Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05773014 -
Digital vs. Speculum Exams for PPROM
|
N/A | |
| Recruiting |
NCT05322252 -
Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial
|
Phase 4 | |
| Not yet recruiting |
NCT02069587 -
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and to Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of Membranes
|
N/A | |
| Recruiting |
NCT06443788 -
Trans-perineal Ultrasound in Assessment of PPROMs
|
N/A | |
| Recruiting |
NCT03819192 -
Predicting EONS in PPROM Patients
|